MedTrace Logo

Evaluation of Presumptive Periodic Treatment (PPT) of Sexually Transmitted Infections (STIs)

NCT04036318 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3022

Last updated 2020-09-10

No results posted yet for this study

Summary

Sexually transmitted infections (STI) are important causes of reproductive health morbidity and mortality, and have long been implicated as major co-factors in the sexual transmission of HIV. Both ulcerative and non-ulcerative STI have been found to be strongly associated with HIV in cross-sectional and prospective studies and hence STI prevention and care are important aspects of HIV prevention.

Periodic Presumptive Treatment of STIS (PPT) where risk populations are presumptively treated with a single dose of Azithromycin+Cefixime in regular intervals of 3 months has been shown to be effective in reducing STI prevalence at population level and has recently been integrated into the National STI guidelines of Tanzania. The USAID funded Sauti program will be one of the first to implement these new guidelines and roll out PPT in high risk populations in selected regions in Tanzania. This study will evaluate the impact of PPT as delivered by the Sauti program on prevalence of STIs in men who have sex with men and female sex workers in Dar es Salaam and Shinyanga respectively.

Conditions

  • Sexually Transmitted Diseases, Bacterial
  • HIV Infections

Sponsors & Collaborators

  • National Institute for Medical Research, Tanzania

    lead OTHER_GOV

Principal Investigators

  • Amani Shao, MD; MPH; PhD · National Institute for Medical Research

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-14
Primary Completion
2019-08-13
Completion
2019-08-13

Countries

  • Tanzania

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04036318 on ClinicalTrials.gov